On November 28, 2022 Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company reported a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Press release, Mirati, NOV 28, 2022, View Source [SID1234624511]). Findings will be presented on December 7 at the 2022 European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology (ESMO IO) Annual Congress as an oral presentation from 2:15 p.m.-2:25 p.m. CET / 8:15 a.m.-8:25 a.m. ET (Presentation #LBA4) during the "Proffered Paper session 1" session of the congress .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mirati Therapeutics will host a Virtual Investor Event following the session on Wednesday, December 7, 2022 at 5:00 p.m. CET / 11:00 a.m. ET / 8:00 a.m. PT.

Investors and the general public are invited to access the live webcast of the presentation at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-254-3590, confirmation code: 1294615. A replay of the presentation will be available approximately 2 hours after the event has ended at the same website.